Is Jasper Therapeutics Stock a Good Investment?
Jasper Therapeutics Investment Advice | JSPRW |
- Examine Jasper Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Jasper Therapeutics' leadership team and their track record. Good management can help Jasper Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Jasper Therapeutics' business and its evolving consumer preferences.
- Compare Jasper Therapeutics' performance and market position to its competitors. Analyze how Jasper Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Jasper Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Jasper Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Jasper Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Jasper Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Jasper Therapeutics Stock
Researching Jasper Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 3.84. Jasper Therapeutics had not issued any dividends in recent years.
To determine if Jasper Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Jasper Therapeutics' research are outlined below:
| Jasper Therapeutics is way too risky over 90 days horizon | |
| Jasper Therapeutics has some characteristics of a very speculative penny stock | |
| Jasper Therapeutics appears to be risky and price may revert if volatility continues | |
| Jasper Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Jasper Therapeutics has accumulated about 16.76 M in cash with (52.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Jasper Therapeutics has a frail financial position based on the latest SEC disclosures |
Jasper Therapeutics Quarterly Cash And Short Term Investments |
|
Jasper Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.83) | (0.88) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (0.82) | (0.78) |
Determining Jasper Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Jasper Therapeutics is a good buy. For example, gross profit margin measures Jasper Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Jasper Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Jasper Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jasper Therapeutics. Check Jasper Therapeutics' Beneish M Score to see the likelihood of Jasper Therapeutics' management manipulating its earnings.
Evaluate Jasper Therapeutics' management efficiency
The company has return on total asset (ROA) of (0.4092) % which means that it has lost $0.4092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7146) %, meaning that it generated substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Total Assets are likely to drop slightly above 63.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.51 | 7.89 | |
| Tangible Book Value Per Share | 7.51 | 7.89 | |
| Enterprise Value Over EBITDA | 0.03 | 0.03 | |
| Price Book Value Ratio | 1.05 | 1.10 | |
| Enterprise Value Multiple | 0.03 | 0.03 | |
| Price Fair Value | 1.05 | 1.10 | |
| Enterprise Value | -19.5 M | -18.5 M |
The strategic initiatives led by Jasper Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 2.199 |
Basic technical analysis of Jasper Stock
As of the 27th of November, Jasper Therapeutics retains the Market Risk Adjusted Performance of 0.0365, risk adjusted performance of 0.0142, and Downside Deviation of 10.09. Jasper Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Jasper Therapeutics variance and potential upside to decide if Jasper Therapeutics is priced fairly, providing market reflects its last-minute price of 0.22 per share. As Jasper Therapeutics appears to be a penny stock we also urge to confirm its total risk alpha numbers.Jasper Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jasper Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kapoor Vishal over two months ago Insider Trading | ||
Mahal Jeetinder Singh over two months ago Disposition of tradable shares by Mahal Jeetinder Singh of Jasper Therapeutics subject to Rule 16b-3 | ||
Carlyle Group Inc. over three months ago Acquisition by Carlyle Group Inc. of 3133333 shares of Jasper Therapeutics at 1.5 subject to Rule 16b-3 | ||
Hoffen Howard I over six months ago Acquisition by Hoffen Howard I of 2300000 shares of Jasper Therapeutics subject to Rule 16b-3 | ||
Emster Kurt Von over six months ago Acquisition by Emster Kurt Von of 47000 shares of Jasper Therapeutics at 1.6 subject to Rule 16b-3 | ||
Hoffen Howard I over six months ago Acquisition by Hoffen Howard I of 200000 shares of Jasper Therapeutics subject to Rule 16b-3 |
Understand Jasper Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Jasper Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0142 | |||
| Market Risk Adjusted Performance | 0.0365 | |||
| Mean Deviation | 3.52 | |||
| Semi Deviation | 4.89 | |||
| Downside Deviation | 10.09 | |||
| Coefficient Of Variation | 14094.67 | |||
| Standard Deviation | 6.16 | |||
| Variance | 37.9 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.92) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0265 | |||
| Maximum Drawdown | 28.18 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 101.86 | |||
| Semi Variance | 23.92 | |||
| Expected Short fall | (8.34) | |||
| Skewness | 0.0088 | |||
| Kurtosis | 2.0 |
| Risk Adjusted Performance | 0.0142 | |||
| Market Risk Adjusted Performance | 0.0365 | |||
| Mean Deviation | 3.52 | |||
| Semi Deviation | 4.89 | |||
| Downside Deviation | 10.09 | |||
| Coefficient Of Variation | 14094.67 | |||
| Standard Deviation | 6.16 | |||
| Variance | 37.9 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.92) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0265 | |||
| Maximum Drawdown | 28.18 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 101.86 | |||
| Semi Variance | 23.92 | |||
| Expected Short fall | (8.34) | |||
| Skewness | 0.0088 | |||
| Kurtosis | 2.0 |
Consider Jasper Therapeutics' intraday indicators
Jasper Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Jasper Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Jasper Therapeutics time-series forecasting models is one of many Jasper Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Jasper Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Jasper Stock media impact
Far too much social signal, news, headlines, and media speculation about Jasper Therapeutics that are available to investors today. That information is available publicly through Jasper media outlets and privately through word of mouth or via Jasper internal channels. However, regardless of the origin, that massive amount of Jasper data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jasper Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jasper Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jasper Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jasper Therapeutics alpha.
Jasper Therapeutics Corporate Management
| William Lis | Ex CEO | Profile | |
| Luca Noto | Senior Operations | Profile | |
| Carol Zoltowski | VP Quality | Profile | |
| Jeetinder MBA | Chief Officer | Profile |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.